Basic Information
| LncRNA/CircRNA Name | UBE2CP3-001 |
| Synonyms | NA |
| Region | NA |
| Ensemble | NA |
| Refseq | NA |
Classification Information
| Regulatory Mechanism | Biological Function | Clinical Application | |||
|---|---|---|---|---|---|
| TF | Immune | Survival | |||
| Enhancer | Apoptosis | apoptosis | Drug | ||
| Variant | Cell Growth | Circulating | 2 | ||
| MiRNA | EMT | Metastasis | |||
| Methylation | Coding Ability | Recurrence |
Cancer&Entry Information
| Cancer Name | glioma |
| ICD-0-3 | NA |
| Methods | qPCR, Western blot, other |
| Sample | gliomas tissues and cell lines |
| Expression Pattern | up-regulated |
| Function Description | Downregulation of UBE2CP3-001 could inhibit cell migration and invasiveness of U87 cells. Downregulation of UBE2CP3-001 in U87 cells also suppressed the cell proliferation and promoted apoptosis . Furthermore, in vivo studies confirmed that knockdown of UBE2CP3-001 could retard the growth of U87 xenograft tumors. Western blot analysis showed that knockdown of UBE2CP3-001 could effectively inhibit the expression of MMP-9 and TRAF3IP2 in U87 glioma cells. |
| Pubmed ID | 30393485 |
| Year | 2018 |
| Title | The function and clinical relevance of lncRNA UBE2CP3-001 in human gliomas. |
External Links
| Links for UBE2CP3-001 | GenBank HGNC NONCODE |
| Links for glioma | OMIM COSMIC |